
    
      1) Determine if a GVHD prophylaxis regimen of IL-2/SIR/TAC enhances in vivo Treg
      differentiation and growth; 2) Study the safety and effects of IL-2/SIR/TAC on the incidence
      of acute and chronic GVHD; 3) Evaluate the influence of dual IL-2 supplementation and
      mammalian target of rapamycin (mTOR) inhibition on T cell-specific signaling pathways and the
      polarization of emerging T helper cells.
    
  